Head-to-head evidence
Lenacapavir vs VH4011499
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Lenacapavir · Sunlenca / Yeztugo
Marketed by Gilead Sciences
NCT04143594 · Phase 2 · completed
The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.
Next expected readout: March 2027 · NCT06749054 (registry estimate)
VH4011499
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.
Next expected readout: August 2028 · NCT06724640 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenacapavir's landscape · VH4011499's landscape